Arcutis Biotherapeutics, Inc. (ARQT)
NASDAQ: ARQT · Real-Time Price · USD
23.90
+0.24 (1.01%)
At close: Sep 4, 2026, 4:00 PM EDT
24.61
+0.71 (2.97%)
After-hours: Sep 4, 2026, 5:20 PM EDT
Arcutis Biotherapeutics Employees
Arcutis Biotherapeutics had 354 employees as of December 31, 2025. The number of employees increased by 12 or 3.51% compared to the previous year.
Employees
354
Change (1Y)
12
Growth (1Y)
3.51%
Revenue / Employee
$1,310,681
Profits / Employee
$80,562
Market Cap
3.00B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 354 | 12 | 3.51% |
| Dec 31, 2024 | 342 | 46 | 15.54% |
| Dec 31, 2023 | 296 | 28 | 10.45% |
| Dec 31, 2022 | 268 | 121 | 82.31% |
| Dec 31, 2021 | 147 | 93 | 172.22% |
| Sep 30, 2021 | 143 | 90 | 169.81% |
| Jun 30, 2021 | 108 | 59 | 120.41% |
| Mar 31, 2021 | 75 | 32 | 74.42% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Zai Lab | 1,784 |
| Beam Therapeutics | 540 |
| Tarsus Pharmaceuticals | 370 |
| Nurix Therapeutics | 317 |
| Immunome | 247 |
| uniQure | 221 |
| Celldex Therapeutics | 198 |
| Disc Medicine | 165 |
ARQT News
- 2 days ago - Arcutis Management to Present at the Morgan Stanley 24th Annual Global Healthcare Conference - GlobeNewsWire
- 3 days ago - Arcutis Biotherapeutics Slides: Corporate presentation - Filings
- 11 days ago - Oruka Therapeutics appoints Todd Edwards as chief commercial officer - TheFly
- 4 weeks ago - Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 weeks ago - Arcutis Biotherapeutics price target raised to $38 from $34 at Morgan Stanley - TheFly
- 4 weeks ago - Arcutis Biotherapeutics price target raised to $36 from $35 at Mizuho - TheFly
- 4 weeks ago - Arcutis Biotherapeutics price target raised to $38 from $35 at Guggenheim - TheFly
- 4 weeks ago - Arcutis Biotherapeutics Earnings Call Transcript: Q2 2026 - Transcripts